Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Q4 2025 Earnings Presentation
20 slides from Pacira Biosciences's earnings presentation, Feb 26, 2026
Slide 1: 4Q25 Earnings Presentation
4Q25 Earnings Presentation PCRX | February 2026
Slide 2: Forward-looking statements and where to find additional information
Forward-looking statements and where to find additional information Any statements in this presentation about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intend
Slide 3: Guiding Principles: Mission and Values
GUIDING PRINCIPLES MISSION We deliver innovative, non-opioid pain therapies to transform the lives of patients. VALUES Every day, we are is the We respect the determined to foundation of diverse talent and who we are the collective power of a Better is possible. 3
Slide 4: Pacira is once again growing with momentum
Pacira is once again growing with momentum Better is possible. 4
Slide 5: Significant cash-generating commercial base advancing pipeline value
SIGNIFICANT CASH-GENERATING COMMERCIAL BASE ADVANCING PIPELINE VALUE 1 2 3 4 5 More than 3 million Double-digit 5-percentage Clinical pipeline Establishing patients treated compounded point gross margin expansion with 5 partnerships per year annual growth rate improvement over 5 novel programs inclu
Slide 6: EXPAREL regional distribution agreement with LG Chem
EXPAREL regional distribution agreement with LG Chem Partnership expands patient access in select Asian-Pacific markets and advances 5x30 strategy • Leading healthcare company with deep surgical & orthopedic expertise 1st wave • Opens access to new markets with proven partner 1. South Korea 2. Thail
Slide 7: HCPs recognize importance of NOPAIN and starting to take action
HCPs recognize importance of NOPAIN and starting to take action 82% 52% 49% 44% view NOPAIN as important for advancing non-opioid stewardship Made changes Added qualifying Changed opioid to perioperative products to prescribing patterns protocols formulary at discharge NOPAIN impact survey fielded i
Slide 8: Implementation of NOPAIN favorably impacting opioid prescribing
Implementation of NOPAIN favorably impacting opioid prescribing 88% 78% 92% 71% believe NOPAIN contributes to reducing opioid prescribing in U.S. Before During At surgery surgery discharge NOPAIN impact survey fielded in 4Q25 collected responses from 744 healthcare professionals, including Directors
Slide 9: Commercial coverage significantly expanded in 2025
Commercial coverage significantly expanded in 2025 NOPAIN provided important initial catalyst, but Commercial coverage is important Covered lives expansion progress Strategic market prioritization 11M TX Top 5 states 4Q YoY volume account for FL growth of 11M 9M CA NJ collectively in NOPAIN these ma
Slide 10: Generating robust body of real-world evidence to highlight EXPAREL value
Generating robust body of real-world evidence to highlight EXPAREL value proposition and expand utilization HEOR study presentations at upcoming congresses Innovations in Genicular Outcomes Registry Capturing clinical and economic data, as well as patient reported outcomes patients enrolled to from
Slide 11: 2026 will be a pivotal year as Pacira enters a data-rich period
2026 will be a pivotal year as Pacira enters a data-rich period Product Target 2026 2027 2028+ Commercial Base Pediatric 0 to <6 PK/Safety Clinical Trial Shoulder OA Phase 3 interim analysis Spasticity Interim analysis Topline readout Knee OA IGOR | Capturing real-world data spanning the patient tre
Slide 12: PCRX-201 has the potential to transform OA treatment
PCRX-201 (enekinragene inzadenovec) has the potential to transform OA treatment A first-of-its-kind, locally-administered gene therapy for the potential treatment of common chronic diseases like OA FDA-approved drugs successfully Robust Phase 1 trial with 72 adult First gene therapy to achieve Local
Slide 13: PCRX-201: Part A of Phase 2 ASCEND study on track
PCRX-201: Part A of Phase 2 ASCEND study on track for topline data end of year Two-part, randomized, double-blind, active-controlled study Part A Part B IA Corticosteroid* IA Corticosteroid* + + Group 1 PCRX-201: 1.4×1010 GC PCRX-201: 1.4×1010 GC N=15(A) N=30(B) Two-part P2 study: IA Corticosteroid*
Slide 14: PCRX-2002: Potentially franchise-enhancing and complementary profile
PCRX-2002: Potentially franchise- enhancing and complementary profile Easy to administer Supplied in a prefilled syringe that requires no preparation. Smooth gel- like consistency makes it easy to spread on the incision Prefilled syringe Rapid onset paired with Remains sustained release Rapid onset
Slide 15: Significant cashflow generation to advance strategy and create shareholder value
Significant cashflow generation to advance strategy and create shareholder value $ in M $ in M 4Q25 FY25 2026 Financial Guidance $156 $575 $600-620 $33 $117 Total Revenue $745-770 $7 $24 Non-GAAP Gross Margins 77-79% Total Revenue $197 $726 Non-GAAP R&D $105-115 Non-GAAP Gross Margins 80% 81% Non-GA
Slide 16: Disciplined capital allocation strategy to drive shareholder value
Disciplined capital allocation strategy to drive shareholder value Driving topline 1 growth • Leverage existing commercial infrastructure Advancing • Therapeutic area focus on musculoskeletal pain and adjacencies 2 innovative • Prioritize accretive in-market assets to leverage established commercial
Slide 17: Pacira is stronger today than it has ever been
Across every dimension core to our business – Pacira is stronger today than it has ever been Collectively all grounded in our Better is possible. 17
Slide 18: Website, Investor toolkit, Social
Website Investor-toolkit Social: X Social: LinkedIn
Slide 19: Appendix
APPENDIX Better is possible. 19
Slide 20: Non-GAAP disclosure
Non-GAAP disclosure Pacira BioSciences, Inc. Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (Non-GAAP) (in thousands) (unaudited) 4Q25 FY25 GAAP net income (loss) $ 1,637 $ 7,034 Interest income (2,295) (22,732) Interest expense (1) 3,892 17,446 Income tax expense (1,066) 9,840 Deprecia